(Q32041116)

5 July 2017

Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study (English)

1 reference

5 July 2017

1 reference

Mertes G

1

1 reference

5 July 2017

1 April 1998

1 reference

Diabetes Research and Clinical Practice

5 July 2017

1 reference

5 July 2017

40

1 reference

5 July 2017

1

1 reference

5 July 2017

63-70

1 reference

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man

5 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900045-X

7 January 2021

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900045-X

7 January 2021

Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900045-X

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900045-X

7 January 2021

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900045-X

7 January 2021

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900045-X

7 January 2021

10.1016/S0168-8227(98)00045-X

Identifiers

DOI

1 reference

5 July 2017

1 reference

PubMed ID

9699092